Repligen (NASDAQ:RGEN) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a report published on Friday, June 21st, BidAskClub reports.

RGEN has been the subject of several other research reports. ValuEngine raised United Overseas Bank from a sell rating to a hold rating in a report on Monday, June 17th. Zacks Investment Research downgraded Hess Midstream Partners from a hold rating to a sell rating in a report on Tuesday, May 14th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $70.50.

Shares of RGEN remained flat at $$85.00 during mid-day trading on Friday. 188,259 shares of the stock traded hands, compared to its average volume of 544,856. The firm has a market cap of $4.01 billion, a price-to-earnings ratio of 116.44, a P/E/G ratio of 5.17 and a beta of 1.10. Repligen has a one year low of $45.00 and a one year high of $87.42. The stock’s 50 day moving average is $78.38. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.26 by $0.02. The company had revenue of $60.63 million during the quarter, compared to the consensus estimate of $55.09 million. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The firm’s revenue for the quarter was up 35.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.17 EPS. Equities research analysts predict that Repligen will post 0.94 EPS for the current fiscal year.

In other Repligen news, Director Glenn L. Md Cooper sold 5,000 shares of the stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total transaction of $334,700.00. Following the transaction, the director now owns 35,975 shares in the company, valued at approximately $2,408,166.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Karen A. Dawes sold 1,295 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the transaction, the director now owns 118,329 shares in the company, valued at approximately $9,152,748.15. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of RGEN. Huntington National Bank bought a new position in Repligen during the 1st quarter worth $25,000. Royce & Associates LP increased its position in shares of Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 145 shares during the period. Mascoma Wealth Management LLC bought a new position in shares of Repligen in the first quarter worth $41,000. Private Capital Group LLC increased its position in shares of Repligen by 675.3% in the first quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 628 shares during the period. Finally, Bronfman E.L. Rothschild L.P. increased its position in shares of Repligen by 16.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 214 shares during the period. Hedge funds and other institutional investors own 84.90% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Investing in Growth Stocks

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.